MyoKardia, Inc, a company focused on developing innovative therapeutics to treat genetic heart disease, today announced the appointment of Mark L. Perry to its board of directors, joining Tassos Gianakakos, Charles Homcy, M.D., and Kevin Starr.
“With more than 30 years of biotechnology experience, Mark brings a wealth of expertise to MyoKardia as we evolve into a fully integrated development company focused on transforming cardiovascular care,” said Tassos Gianakakos, chief executive officer of MyoKardia.
Help employers find you! Check out all the jobs and post your resume.
